search
GIPR
Trends
- 1Insilico Medicine unveils AI-designed obesity drug candidate ISM1354▼Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease
Insilico Medicine has nominated ISM1354, a GIPR antagonist designed using its artificial intelligence drug discovery platform, as a preclinical candidate for obesity and related metabolic diseases. The company says the molecule was generated and optimised end-to-end with generative AI tools. It adds to a growing slate of AI-discovered drugs moving toward clinical development, as pharmaceutical firms race to apply machine learning to the booming obesity treatment market.
- 2Insilico Medicine picks AI-designed obesity drug candidate ISM1354▼Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity
Drug discovery company Insilico Medicine has nominated ISM1354, an AI-designed GIPR antagonist, as a preclinical drug candidate for the treatment of obesity. The compound was developed using the firm's artificial intelligence drug discovery platform, adding to a growing pipeline of AI-generated molecules advancing toward clinical development for metabolic disease.